INNV vs TLX: fair value comparison
InnovAge Holding Corp. and Telix Pharmaceuticals Limited · Updated 2026-10-19
INNV is still awaiting a full valuation verdict under our six-validated-windows standard. TLX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, TLX currently ranks higher by quality score.
| INNV | TLX | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $8.85 | $10.69 |
| 12-month range | $3.99–$12.11 | $6.41–$12.83 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #131 of 301 Healthcare | #130 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: INNV fair value analysis · TLX fair value analysis